Ronald Penczek - Elevance Health Controller VP
| ELV Stock | USD 403.60 6.12 1.54% |
Insider
Ronald Penczek is Controller VP of Elevance Health
| Age | 59 |
| Address | 220 Virginia Avenue, Indianapolis, IN, United States, 46204 |
| Phone | 833 401 1577 |
| Web | https://www.elevancehealth.com |
Ronald Penczek Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ronald Penczek against Elevance Health stock is an integral part of due diligence when investing in Elevance Health. Ronald Penczek insider activity provides valuable insight into whether Elevance Health is net buyers or sellers over its current business cycle. Note, Elevance Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell Elevance Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ronald Penczek over a week ago Disposition of 1055 shares by Ronald Penczek of Elevance Health at 475.17 subject to Rule 16b-3 | ||
Ronald Penczek over six months ago Disposition of tradable shares by Ronald Penczek of Elevance Health at 454.35 subject to Rule 16b-3 |
Elevance Health Management Efficiency
The company has Return on Asset of 0.0584 % which means that on every $100 spent on assets, it made $0.0584 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.155 %, implying that it generated $0.155 on every 100 dollars invested. Elevance Health's management efficiency ratios could be used to measure how well Elevance Health manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to climb to 2.11 in 2024, whereas Return On Tangible Assets are likely to drop 0.06 in 2024. At this time, Elevance Health's Other Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 45.7 B in 2024, whereas Intangible Assets are likely to drop slightly above 8.3 B in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Theodore Samuels | Centene Corp | 66 | |
| Laurie Havanec | CVS Health Corp | 63 | |
| Dinesh MD | Alignment Healthcare LLC | 55 | |
| Kenneth Burdick | Centene Corp | 62 | |
| Christopher Coughlin | Centene Corp | 68 | |
| JohnPaul Felter | Humana Inc | 41 | |
| Jim Murray | Centene Corp | N/A | |
| Timothy Wheatley | Humana Inc | 56 | |
| Patricia Lewis | UnitedHealth Group Incorporated | 57 | |
| Wayne Frederick | Humana Inc | 49 | |
| Amy Fry | Humana Inc | N/A | |
| Richard Cross | Alignment Healthcare LLC | N/A | |
| Dave Reynolds | Molina Healthcare | N/A | |
| William DeLaney | Cigna Corp | 65 | |
| Jonathan Dinesman | Centene Corp | N/A | |
| David Thomas | Centene Corp | 58 | |
| Charles Berg | Cigna Corp | 63 | |
| Jennifer Bazante | Humana Inc | 59 | |
| Ashlee Knuckey | Centene Corp | N/A | |
| Brian Maddy | Molina Healthcare | N/A | |
| Barbara Brasier | Molina Healthcare | 62 | |
Management Performance
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0584 |
Elevance Health Leadership Team
Elected by the shareholders, the Elevance Health's board of directors comprises two types of representatives: Elevance Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Elevance. The board's role is to monitor Elevance Health's management team and ensure that shareholders' interests are well served. Elevance Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Elevance Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Chris Rigg, SVP Division | ||
| Ronald Penczek, Controller VP | ||
| Scott Anglin, Treasurer SVP | ||
| John Gallina, Ex CFO | ||
| Julie Goon, Senior Affairs | ||
| Felicia Norwood, Executive Benefits | ||
| Charles Kendrick, Executive Benefits | ||
| Blair Todt, Executive Officer | ||
| Udi Manber, Chief Officer | ||
| Stephen CFA, Vice Relations | ||
| Gloria McCarthy, Exec Officer | ||
| Kyle Weber, Chief Officer | ||
| Peter Esq, Executive CarelonRx | ||
| Scott Towers, President Business | ||
| Beth Chesmha, President Indiana | ||
| Paul Marchetti, President CarelonRx | ||
| Gail Boudreaux, CEO President | ||
| Anil Bhatt, Chief Officer | ||
| Mark Kaye, Executive CFO |
Elevance Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Elevance Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0584 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 111.47 B | ||||
| Shares Outstanding | 231.92 M | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 91.64 % | ||||
| Number Of Shares Shorted | 2.85 M | ||||
| Price To Earning | 19.27 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elevance Stock Analysis
When running Elevance Health's price analysis, check to measure Elevance Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevance Health is operating at the current time. Most of Elevance Health's value examination focuses on studying past and present price action to predict the probability of Elevance Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevance Health's price. Additionally, you may evaluate how the addition of Elevance Health to your portfolios can decrease your overall portfolio volatility.